Iboga vs Ibogaine: The Difference Between Plant and Alkaloid

Iboga is the plant. Ibogaine is one alkaloid extracted from it. The root bark of Tabernanthe iboga contains more than 30 alkaloids — ibogaine is the primary psychoactive compound, but it is not the only pharmacologically active one. When people ask which they should use, the question usually misframes the choice: whole-plant iboga preparations and isolated ibogaine are not interchangeable options. They produce different experiences, have different durations, and are used in different contexts.

What iboga is

Tabernanthe iboga is a slow-growing shrub native to the rainforests of Central Africa — primarily Gabon, Cameroon, and the Democratic Republic of Congo. The root bark is the part used ceremonially and therapeutically. It contains more than 30 distinct alkaloids, of which ibogaine is the most studied. Others — tabernanthine, ibogamine, coronaridine, voacangine, and noribogaine among them — are pharmacologically active in varying degrees and interact with each other in ways that are not fully understood.

In traditional Bwiti use, the root bark is prepared and administered as a total alkaloid extract — the full spectrum of compounds present in the plant. This is not the same as taking isolated ibogaine. The Bwiti tradition has worked with iboga ceremonially for centuries. The accumulated knowledge about how to work with this medicine, how to prepare participants, and how to hold what the medicine produces is embedded in the tradition — not in a prescribing protocol.

When the term "iboga ceremony" is used, it typically refers to ceremony using whole-plant preparations — root bark or total alkaloid extract. The ceremonial context, the setting, and the tradition it draws from are not incidental to the experience. They are constitutive of it.

For the full account of the Bwiti tradition and what iboga has meant in its cultural context for centuries, read the guide to the Bwiti tradition and the sacred root bark.

What ibogaine is

Ibogaine is the primary psychoactive alkaloid isolated from the iboga root bark. It is typically produced as ibogaine hydrochloride — ibogaine HCl — a standardised compound that can be dosed with pharmaceutical precision. This predictability is what makes ibogaine the preferred preparation in clinical research settings, where controlled dosing is required for valid results.

The compound acts on multiple neurological systems simultaneously: dopamine, serotonin, acetylcholine, NMDA receptors, and sigma receptors. It is this pharmacological breadth — not a simple mechanism like an SSRI or an opioid antagonist — that produces effects qualitatively different from anything else available.

The 2023 Stanford study, published in Nature Medicine, used ibogaine in a clinical context. In 30 special operations veterans with treatment-resistant PTSD, traumatic brain injury, and depression, it found an 88% average decrease in PTSD symptoms, 87% in depression symptoms, and 81% in anxiety at one month post-treatment. That study used pharmaceutical ibogaine HCl — not whole-plant preparations. That distinction matters when interpreting the research.

After the active experience, ibogaine converts in the body to noribogaine — an active metabolite that remains biologically present for weeks to months. This extended window is the most plausible explanation for why ibogaine produces lasting changes in craving and mood well beyond the ceremony.

How the experience differs

The most frequently cited distinction is duration: an ibogaine ceremony (isolated compound) typically runs 12–24 hours of active experience. Traditional whole-plant Bwiti initiation can extend 24–36 hours or longer — in initiatory contexts, multiple nights over several days. In Western ceremonial settings, whole-plant iboga experiences tend to fall in a similar 12–24 hour active window to ibogaine, though the onset and quality differ.

The more substantive difference is in the character of the experience. Practitioners who have worked with both preparations consistently describe whole-plant iboga as having a broader quality — more layered, with subsidiary content alongside the primary autobiographical review. Isolated ibogaine is often described as more direct: faster onset, a more immediate confrontation with the material that needs addressing.

The mechanism behind this is sometimes called the entourage effect — by analogy to cannabis research, where multiple compounds interacting appear to produce a more complex response than any single compound in isolation. In iboga, tabernanthine and other alkaloids appear to modulate the experience in ways that add textural depth and may attenuate some of the more physically demanding aspects of isolated ibogaine. Whether this produces better clinical outcomes than isolated ibogaine is an open research question. The published clinical literature is primarily based on ibogaine HCl. The ceremonial tradition is based on whole-plant preparations.

People who arrive expecting the whole-plant preparation to be gentler — or more "authentic" and therefore easier — are consistently surprised. The medicine does not accommodate avoidance regardless of the form it takes.

Recovery after either preparation takes 2–3 days. Noribogaine remains biologically active for weeks to months after either form. The integration period — and what is done with it — applies equally to both.

Which preparation is used for what

Clinical research and most formal ibogaine treatment programmes — particularly in Mexico — use ibogaine HCl. Precise dosing per kilogram of body weight is more reliable, and the pharmacokinetics are better understood. The Stanford study and most published research use ibogaine HCl for this reason.

For ceremonially-rooted treatment — in contexts informed by the Bwiti tradition — total alkaloid extract or root bark preparations are more common. These are not inferior formulations. They are different preparations that require experienced practitioners who understand variable alkaloid content and can exercise the dosing judgment that pharmaceutical precision replaces.

At ExploreBwiti in Vancouver, we work with iboga in the ceremonial context — whole-plant preparations, rooted in the Bwiti tradition. This is not a clinical ibogaine administration. The medical screening requirements are identical. But the context is ceremonial, not clinical — and that context shapes what the experience is and what is possible within it.

Both preparations are used for opioid dependence, PTSD, and treatment-resistant depression. The choice between them is less often a clinical decision than a contextual one: what kind of container, what kind of practitioner, what relationship to the tradition. The ceremony page explains what working with iboga at ExploreBwiti specifically involves.

For a full breakdown of what ibogaine treatment — in both ceremonial and clinical contexts — involves, read the ibogaine treatment guide.

Safety: what applies to both

The same core safety requirements apply regardless of whether you are working with whole-plant iboga or isolated ibogaine. The primary risks are the same.

Both preparations share the same cardiac risk profile: ibogaine alkaloids prolong the QT interval, which can produce fatal arrhythmia in people with pre-existing cardiac conditions. EKG and cardiovascular screening is required before any ceremony or treatment. Any provider — whether offering whole-plant iboga or isolated ibogaine — who does not require cardiac screening is not operating safely. This is not a debatable point, and it is not a grey area.

SSRIs and SNRIs are absolute contraindications for both preparations. The risk of serotonin syndrome is real and potentially fatal, and it applies regardless of whether the source is whole-plant or isolated.

The one area where isolated ibogaine offers a practical advantage is dosing precision. Pharmaceutical ibogaine HCl is typically dosed at 10–25 mg per kilogram of body weight, depending on the protocol. Whole-plant preparations require experienced practitioners who understand the variable alkaloid content and can adjust accordingly. This is a reason to be rigorous about who conducts your ceremony — not a reason to avoid whole-plant preparations.

The clinical literature on PubMed consistently shows the same finding: serious adverse events during ibogaine treatment are concentrated among providers who did not conduct cardiac screening. Not among those who used whole-plant versus isolated preparations.

Who this is not for

The question of iboga versus ibogaine becomes secondary to a more immediate question: are you an appropriate candidate for either? The absolute contraindications apply to both preparations equally.

• QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction — absolute contraindications for both. EKG identifies this before ceremony, not during it.
• Current SSRIs or SNRIs — absolute contraindications for both. The risk of serotonin syndrome applies regardless of preparation. A supervised taper, conducted with your prescribing physician, is required before either form of treatment is possible. There are no exceptions.
• Methadone — a specific supervised transition protocol is required before either form is possible.
• Acute psychiatric instability — active psychosis, florid paranoia, or severe acute suicidal ideation. Both preparations amplify what is present.
• Severe liver or kidney disease — both preparations are metabolised through the same pathways. Absolute contraindication.
• Pregnancy.

The conversation that ends in "this is not the right path for you at this moment" is one of the most important things the intake process does. Not everyone who applies is an appropriate candidate — and saying that directly, without softening it, is not rejection. It is accurate information delivered at the right time.

The FAQ covers these contraindications in detail, including what to do if you are currently on SSRIs and want to pursue this work.

Is this right for you?

If you are trying to understand the distinction between iboga and ibogaine, the short version is: iboga is the whole plant, ibogaine is the primary isolated alkaloid. The choice between them in a treatment context is rarely the most critical variable. The critical variables are whether you are medically appropriate, what conditions you are addressing, and whether the provider has the infrastructure to make the process safe.

Start with the FAQ for the full account of the screening process and who it is not appropriate for. If you are considering working with iboga in a ceremonial context in Vancouver, the ceremony page explains what that involves specifically. When you are ready to begin that conversation, the application is where it starts. We respond personally to every application within 2–3 business days.

The integration process after either form of treatment is not separable from the ceremony itself. The integration page covers why that matters and what it involves.